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Abstract
Background: Chordomas of the skull base are relative rare lesions of the bones. Surgical resection is the primary
treatment standard, though complete resection is nearly impossible due to close proximity to critical and hence
also dose limiting organs for radiation therapy. Level of recurrence after surgery alone is comparatively high, so
adjuvant radiation therapy is very important for the improvement of local control rates. Proton therapy is the gold
standard in the treatment of skull base chordomas. However, high-LET beams such as carbon ions theoretically
offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors.
Methods/design: This clinical study is a prospective randomised phase III trial. The trial will be carried out at
Heidelberger Ionenstrahl-Therapie centre (HIT) and is a monocentric study.
Patients with skull base chordoma will be randomised to either proton or carbon ion radiation therapy. As a stan-
dard, patients will undergo non-invasive, rigid immobilization and target volume delineation will be carried out
based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment (acceler-
ated dose) will be 63 Gy E ± 5% and 72 Gy E ± 5% (standard dose) in proton therapy respectively. Local-progres-
sion free survival (LPFS) will be analysed as primary end point. Toxicity and overall survival are the secondary end
points. Additional examined parameters are patterns of recurrence, prognostic factors and plan quality analysis.
Discussion: Up until now it was impossible to compare two different particle therapies, i.e. protons and carbon
ions directly at the same facility.
The aim of this study is to find out, whether the biological advantages of carbon ion therapy can also be clinically
confirmed and translated into the better local control rates in the treatment of skull base chordomas.
Trial registration: ClinicalTrials.gov identifier: NCT01182779
Background
Chordomas (1 - 4% of all malignant bone tumors) of the
skull base are relative rare lesions of the bones. The
incidence is around 100 new cases per year in Germany
and 0.08/100000 in the US corresponding to around 300
new cases per year [1]. Chordomas arise from embryo-
nic remnants of the notochord and are found at the
base of the skull area in 35% of all cases. According to
the histopathological findings, chordomas are divided
into conventional (most common), chondroid and dedif-
ferentiated types [2,3]. Histological differentiation
between chordomas and chondrosarcomas is difficult
and must contain immunhistochemical tests [4]. Chor-
doma is immunopositive for epithelial markers like cyto-
keratin and endothelial membrane antigen (EMA),
whereas chondrosarcoma is negative for both. Both
chordomas and chondrosarcomas can be positive for S-
100 and vimentin.
The average age at the diagnosis is 49 years for base
of skull localization. Also, the base of the skull is the
most common localisation of chordomas in children
and adolescents. In children and adolescents chordomas
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may behave more aggressively [5]. Men are affected
more frequently than women.
Surgical resection is the primary treatment standard,
though complete resection is nearly impossible due to
close proximity to critical and hence also dose limiting
organs for radiation therapy i.e. optic nerves, chiasm
and brainstem. Level of recurrence after surgery alone is
with reported rates between 50% and 100% [6] compara-
tively high, so adjuvant radiation therapy is very impor-
tant for the improvement of local control rates in the
primary treatment even after complete resection.
Tumour volume is an important prognostic factor,
hence a tumour debulking is usually required before
radiation therapy application [7]. Other prognostic rele-
vant risk factors are the histological tumour type, resec-
tion status, gender, and the age of the patient [8,9].
Radiation resistance is a common characteristic of
chordomas [10,11], so high total doses are needed to
achive acceptable local control rates after radiotherapy.
Conformal precision and image guided radiation therapy
techniques provide a safe technique for dose escalation
[12]. The physical characteristics of carbon ions or pro-
tons such as inverted dose profile allow steep dose gra-
dients and therefore provide further benefit in this field
by potentially reducing toxicity.
So far, proton therapy is the gold standard in treat-
ment of rare skull-base tumours like chordoma and low
grade chondrosarcoma. The Loma Linda University
Medical Center (LLUMC) [13] and the Massachusetts
General Hospital (MGH) in Boston [14] have the largest
experience in particle therapy for these entities. 3-year
local control for chordomas after fractionated proton
radiation therapy in 33 patients at LLUMC was 67% and
the actuarial 5 year survival rate was 79% respectively
[14]. The outcome of 519 cases of chordomas and chon-
drosarcomas of the skull base including 290 chordomas
treated with a combination of proton and photon ther-
apy at MGH/HCL shows a significant difference in local
control and survival rates between the patients with
chordoma and chondrosarcoma. 5- and 10-year local
progression free survival was 98% and 94% for chondro-
sarcomas and 73% and 54% for chordomas [13,14].
Proton therapy results from PSI in Villingen, Switzer-
land were published by Weber et al. and showed 3 year
local control rates of 87.5% for chordomas. However,
the treated tumour volumes with a median GTV of 16.4
ml were relatively small. 29 patients, among them 18
patients with chordoma were treated to a median target
dose of 74 GyE. The 3-year actuarial PFS rate for the
entire patient cohort was 90% [15].
Carbon ions though, have a higher biological effective-
ness than either protons or photons, which might
improve the results of these radio-resistant tumours
[16]. Carbon ion therapy is available only at the National
Institute of Radiological Sciences (NIRS) in Japan and
up to July 2008 has been available at the Gesellschaft
für Schwerionenforschung (GSI) Darmstadt in Germany.
The experience of our Japanese colleagues is limited to
40 patients with chordoma and chondrosarcoma of the
skull base who could be treated effectively and without
serious side effects [17]. NIRS beam delivery technique
relies on passive scanning necessitating various modula-
tors to adjust for treatment depth and tissue inhomo-
geneities within the beam path.
In comparison to the Japanese centres, the facility at
GSI as well as the Heidelberger Ionenstrahl-Therapie
centre (HIT) relies on active beam delivery using the
raster-scan technique. In prior series, each treatment
plan was biologically optimized at GSI as well as at HIT
(Figure 1). About 300 patients with base of skull chor-
domas and chondrosarcomas have been treated so far.
Initially, these patients were treated within a clinical
Phase I/II study. This study was able to demonstrate
excellent clinical results and carbon ion therapy became
approved as the best therapy available in Germany. The
actuarial local control rates for the chordoma patients
after 3 and 5 years were 80.6% and 70%, the 3 and 5
year overall survival rates were 91.8% and 88.5%, respec-
tively [18].
Methods and Design
Primary objectives/endpoints of the study
The primary objective of this study is to evaluate, if the
innovative therapy (carbon ion irradiation) in chordomas
is superior to the standard proton treatment with
respect to the Local-progression free survival (LPFS)
defined as time from the randomisation to observed
local recurrence or death from any cause in the absence
of documented local disease progression. Local recur-
rence defined as MRT or CT - morphological tumour
progress in the former irradiated region. A 10% increase
in the LPFS is considered clinically relevant assuming
that the LPFS rate for the proton therapy is 70%.
Secondary objectives of the study
1. Assessment of overall survival, progression free
and metastasis free survival, patterns of recurrence,
local control rate and morbidity.
2. Prognostic factors, definition of patients who will
benefit from the adjuvant therapy, risk group
definition.
3. Plan quality (target coverage, sparing of organs at
risk, integral dose).
Study design/concept
The study is a double arm prospective randomised clini-
cal phase III study of patients with chordomas of the
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skull base. Study patients are selected according to the
inclusion criteria of the study protocol. After careful
review of the patient reports and results of the addi-
tional examinations eligibility of a patient is determined.
Patients matching the eligibility criteria and willing to
participate are registered. These patients are subse-
quently randomised to one of the two treatment arms
(arm A: carbon ion therapy, arm B: proton therapy).
Arm A: carbon ion therapy with a total target dose of
63 Gy E ± 5% to the PTV1 (s. also target definition).
The PTV2 will receive a total carbon ion dose of 45 Gy
E.
The patients entered in Arm B will receive proton
therapy with the same target definition concept. The
total proton dose will be 72 Gy E ± 5%. The PTV2 will
receive a total dose of 50 to 56 Gy E in conventional
fractionation (s. also dose prescription).
Accrual period for the trial will be approximately 5
years. Our study design contains interim analysis after
50% of the predicted events have occurred.
Figure 1 Typical dose distribution of carbon ion therapy by clivus chordoma patient (axial view and dose legend; red line defines
CTV; both eyes, optic nerves and brain steam are also shown).
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Inclusion criteria
- Karnofsky Performance Score ≥60%
- Age >18 years and <80 years
- Informed consent signed by the patient
- Histological confirmation of chordoma with infiltra-
tion of the skull base.
Exclusion criteria
- Inability to understand the aims of the study, no
informed consent
- Prior RT of skull base region
- Other malignancies with disease-free interval < 5
years (excepting pre-cancerous lesions)
- Participation in another trial
- Pregnancy
- Simultaneous CHT or Immunotherapy.
Risk group definition
Secondary objectives of the study will be explorative
analysed also according to risk groups mentioned in
Table 1.
Randomisation
The randomisation will be done using the on-line ran-
domisation tool (Randomizer.at) which is self-serve and
runs exclusively on the Internet. An on-screen form
with patient details will be completed. The treatment
allocation will be immediately notified. The randomisa-
tion will be performed regarding treatment arms A and
B. Stratification parameters include the following cri-
teria: age (< 30, ≥ 30 years) and gender.
As this is an open-label study there will be no blinding
of treatment assignment.
Reference Committee
In order to monitor specific aspects of the current trial
the Data Monitoring Committee (DMC) will be estab-
lished. The work of Date Monitoring Committee will be
based on the Guideline on Data Monitoring Committees
EMEA/CHMP/EWP/5872/03. The DMC will be com-
posed of independent experts in the field of radiation
oncology, assessing the progress of the trial and avail-
able safety data. The mission of the DMC will be to
ensure the ethical conduct of the trial and to protect the
safety interests of patients in this trial.
Radiation therapy
Immobilisation
Patients will be immobilized using a precision head
mask to ensure high repositioning accuracy of the target
volume and adjacent structures for carbon ion and pro-
ton RT. Safety margins around the clinical target
volume (CTV) will be determined individually for each
patient. Positioning accuracy will be controlled using
orthogonal x-rays or cone-beam-CTs. Set-up deviations
will be corrected prior to irradiation by correction with
the vector of the robotic table.
Treatment planning examinations/Target definition
The treatment planning CT (obligate native CT, CT
with contrast facultative) and MR - Examination (MRT
- compulsory sequences - axial T1 post gadolinium and
T2 fat saturated or Flair) will be performed in treatment
position using the immobilisation device and will be co-
registered. The treatment planning CT will consist of
continuous 3 mm slices obtained in a stereotactic or vir-
tual simulation set-up.
The delineation of organs at risk and target volume
definition will be done on the basis of CTs and MRI
scans. The PTV1 should include the GTV (entire resi-
dual tumour) and a 1-2 mm safety margin. PTV2
includes the PTV1 with individual safety margin based
on surgical and histological reports, and MR-images to
account for subclinical disease. The PTV2 includes the
whole clivus and the prevertebral muscles down to the
basis of the second cervical vertebra in any case. Normal
tissue constrains will be defined as follows: eyes, optic
nerves, chiasm, brainstem, spinal cord obligatory, tem-
poral lobes, mandible, salivary glands and others faculta-
tively. An overlap of the PTV and the OAR needs to be
avoided.
Carbon ion/Proton RT
Carbon ion RT planning is performed using the treat-
ment planning software including biological plan opti-
mization for carbon ions. Two to maximum four
irradiation fields will be chosen. At HIT the intensity-
controlled raster-scan system will be used for beam
application. Considering the tolerance dose to organs at
risk a dose of 63 Gy E ± 5% in 20-22 fractions for car-
bon ions and 72 Gy E ± 5% in 34-37 fractions for pro-
tons for chordoma patients will be prescribed to the
maximum of the calculated dose distribution for the tar-
get volume (PTV1). Treatment planning aims at cover-
age of the PTV1 and PTV2 with the 95%-isodose line of
the prescribed dose.
For carbon ion therapy dose specification is based on
biologic equivalent dose because of the higher relative
biologic effectiveness (RBE) of carbon ions, which differs
Table 1 Risk group characterization
Low-risk High-risk
Age > 30 years Age ≤ 30 years
Male chordoma Female chordoma
No OAR compression Compression of OAR
Primary tumour Recurrent tumor
Tumour size < 70 ml Tumour size > 70 ml
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throughout the target volume due to its dependence on
various factors. RBE will be calculated for each voxel
throughout the target volumes and biological optimiza-
tion will be performed. The dose prescription used is
related to the isoeffective dose Gy E using daily fractions
of 3 Gy E and a weekly fractionation of 4-6 × 3 Gy E.
For proton therapy RBE of 1.1 will be used using daily
fractions of 2 Gy E and a weekly fractionation of 4-6 ×
2 Gy E.
Evaluation of DVH for the dose distribution will be
performed with regards to assess plan quality. Maximum
chiasm dose, maximum right and left optic nerves dose,
maximum brain steam dose, median brain steam dose,
maximum dose to spinal cord, median dose to spinal
cord will be reported.
Dose prescription
Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E/d, 4-6
days a week, 15 fractions
Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7
fractions a 3 Gy E.
Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E/d,
4-6 days a week, 28 fractions
Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9
fractions a 2 Gy E.
Dose constraints to organs at risk for both arms
Dose constraints to organs at risk (OAR) are estimated
considering the experience of our institution as well as
the data reported by Emami et al. [19] (Table 2).
Organization, Workflow and Follow-up
Patient data will be collected and documented pseudo-
nymously using electronic data processing (e.g. patient
initials, date of birth and study number) at the study
office at HIT. Table 3 presents a brief workflow.
After randomisation the study number will be
assigned.
The following study data will be collected at the study
office at HIT:
1. Medical reports including pathology reports and
results of staging and additional pre-treatment
examinations
2. Documentation of RT (dose distributions and
DVH) and position checks
3. Prescribed total target dose and fraction doses,
treatment interruptions >4 days
4. Toxicity data
5. Follow-up forms
6. Trial-related documentation including severe AE
(CTCAE Grad ≥ 3) will be reported immediately to
the study office and the principal investigator of the
study
7. The date of local recurrence (MRT or CT - mor-
phological tumour progress in the former irradiated
region), distant metastases or death of the patient
will be reported and documented.
Local recurrences will be confirmed radiologically and
histologically whenever possible. At least two medical
doctors (radiation oncologist and/or radiologist) will be
required to judge of the recurrence or toxicity.
Every patient is followed for LPFS and trial-related
AEs for a time period of 8 years. Furthermore, patients
will be followed for survival and locoregional recur-
rences for a time period of 8 years after completion of
the irradiation.
The first and the second follow-up examination will
be performed 4-6 weeks and 3 months after completion
of RT (follow-up 1 and 2). Follow-up examinations will
then be scheduled after 6 months (follow-up 3), 9-12
months (follow-up 4), and then once a year for further
6 years (follow-up 5, 6 and 7). Additional visits will be
scheduled as necessary. Acute toxicity is assessed at
least weekly during RT and documented at the end of
the RT series, 6 weeks after completion of RT and 3
months after RT. Late toxicity will be documented in
regular intervals of 6 or 12 months during the observa-
tion period. All the patients will be observed for radia-
tion specific acute and late AEs for the time of at least 8
years after irradiation. The maximum grade of toxicity
will be determined for each patient.
The Common Terminology Criteria for Adverse
Events V4.0 (CTCAE V.4.0) will be used to grade acute
toxicity from radiation therapy. The criteria are relevant
from the 8th irradiation day until day 90, i.e. until the
1st follow-up visit. Thereafter, the RTOG/EORTC Cri-
teria of Late Effects will be utilized. All acute radiation
effects will be documented on an Acute Radiation
Effect-Form. In addition, the AE-Form and/or SAE-
Form will be filled out. RTOG/EORTC Late Morbidity










Brainstem ≤ 54 Gy with 1% of Volume allowed to receive
>54 Gy, with Dmax ≤ 60 Gy
Brainstem center <50 Gy
Spinal cord ≤ 45 Gy with 1% of Volume allowed to receive
>45 Gy, with Dmax ≤ 50 Gy
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Scoring Scheme will be used to grade toxicity from
radiation therapy occurring later than 90 days after its
start, i.e. beyond the 1st follow-up visit. All late radia-
tion effects will be documented on a Late Radiation
Effect-Form. In addition, an AE-Form and/or SAE-Form
will be filled out, if late radiation effects appear.
The follow-up examinations contain:
- Medical history
- Clinical examination
- MRI or CT of the head
- Documentation of acute side effects/AE (CTCAE
V.4.0) up to 90 days after RT
- Documentation of late side effects/AE (RTOG/
EORTC) after 90 days after RT
- Reporting/documentation of acute grade 3 or 4 toxi-
city or grade 3, 4 or 5 late effects.
Study duration and interruption criteria
Accrual period for the trial will be approximately 5 years
starting on autumn 2010. The study ends with the
enrollment of planned 344 patients. Our study design
contains interim analysis after observation period of 7
years. Definite assessments of LPFS, survival and for
radiation specific AEs will be possible approximately 8
years after completion of radiation therapy of the last
recruited patient.
The individual reasons for the study interruption are
the patient dead or the withdrawing agreement of the
patient to participate in the study.
With proven recurrence of disease or the development
of distant metastases, the patient will be censored for
our study and will be eligible for any additional appro-
priate therapy or inclusion in other investigative proto-
cols, but should still be followed in order to document
survival and radiation specific AEs.
The study can be early terminated under following
considerations:
- high incidence of unknown AEs or increase in
known AEs with the disadvantageous proportion
between risk and benefits of the proposed radiation
therapy;
- unacceptable high rates of SAEs;
- other reasons challenging the ethical basis;
- official decision.
All subjects who have adverse events, whether consid-
ered associated with the therapy, must be monitored to
determine the outcome. The clinical course of the adverse
event will be followed up according to accepted standards
of medical practice, even after the end of the period of
observation, until a satisfactory explanation is found or the
investigator considers it medically justifiable to terminate
follow-up. Should the adverse event result in death, a full
pathologist’s report should be supplied, if possible.
Each adverse event occurring in connection with the
therapy has to be documented, independent of the cause.
Statistical Considerations and Analysis
Study Hypothesis
This study is designed to demonstrate that carbon ion
therapy can significantly improve LPFS compared with
proton therapy in the treatment of skull base chordo-
mas. Primary objective is the comparison of the two
treatment groups.
Null hypothesis H0: The survival functions of LPFS of
the two therapies are equal, hazard ratio = 1.
Alternative hypothesis H1: The survival functions of
LPFS of the two therapies are not equal, hazard ratio ≠
1.
Table 3 Workflow time table
Approval of ethics committee
↓
Diagnosis of chordoma of the skull base and completion of pre-radiation treatment examinations (biopsy, operation, staging)
↓




Arm A: carbon ion RT (63 Gy E ± 5%, fractionation 4-6 × 3.0 Gy E)
Arm B: proton RT (72 Gy E ± 5%, fractionation 4-6 × 2.0 Gy E)
↓
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Sample Size Determination
The sample size is calculated on the basis of the follow-
ing assumptions:
• LPFS rate 5 years after radiation therapy of 70% 1)
for proton therapy, hazard l1 = 0.0713, and 80% for
carbon ion therapy, hazard l2 = 0.0446 (hazard ratio
= 1.599).
• Recruitment period of 5 years, with constant
accrual rate of 20% patients per year and a follow-up
time of 8 years.
• One interim analysis according to a group sequen-
tial design with two stages.
Formula of Schoenfeld [20,21] used for the calculation
of the number of accumulated events. For a two-sided
logrank test with an overall two-sided significance level
of 0.05 (including interim and final analyses) and power
of 0.80, 143 events are required. The critical values and
the test characteristics of the group sequential test
design were calculated for an O’Brien and Fleming type
alpha spending function. The computation assumes
equal allocation to the two groups (n2/n1 = 1). Assum-
ing an accrual time of 5 and a maximum observation
time of 13 years a total of 319 patients is expected to
yield the necessary number of events if the accrual rate
is constant. Under these assumptions, the time point of
the interim analysis should be 7 years after the first
patient is entered. The ADDPLAN, Version 4.0 calcula-
tor was used for the sample size estimation. With the
assumption that approximately 7% of the patients will
be lost to follow-up a total of 344 patients will be
needed to accumulate 143 events.
Analysis Populations and General Considerations
Analysis populations will be defined as follows:
The ITT population will include all patients who are
randomised, with radiation therapy administration
designated according to initial randomisation, regard-
less of whether patients receive study treatment or
receive a different treatment from that to which they
were randomised. This will be the primary population
for evaluating all efficacy endpoints as well as subject
characteristics.
The safety population consists of all subjects who
received at least one dose of irradiation administration
designated according to actual study treatment received.
The PP population will consist of all subjects of the
ITT population who completed the particle therapy,
have at least 2 post-baseline assessments regarding the
primary endpoint without pre-specified (in the statistical
analysis plan), selected major protocol deviations
thought to impact on efficacy analysis.
The statistical analysis will be done as soon as the
database has been declared to be complete and accurate
and has been locked. The details of the analysis will be
laid out in the statistical analysis plan, which will be
finalized and approved prior to the database lock. It has
to be authorized before by the biometrician and the
principle investigator. Missing values will not be
replaced or imputed. For patients with incomplete fol-
low-up, time to last follow-up date will be used as the
censoring time in the analysis of time-to-event data.
Efficacy Analysis
Primary efficacy analysis
LPFS is defined as the time from date of randomisation
to local recurrence or death from any cause in the
absence of documented local disease progression. LPFS
will be censored on the date of the last tumour assess-
ment on study for patients who do not have local
tumour progression and who do not die while on study.
A log-rank test (two-sided) will be used to compare
LPFS between the two treatments. The LPFS-rates will
be derived from the Kaplan Meier estimate [22] and the
confidence intervals will be calculated using Green-
wood’s formula.
Secondary efficacy analyses
A sensitivity analysis will be performed on the primary
efficacy endpoint to assess the impact of protocol devia-
tions using the per protocol analysis set.
A hazard ratio with 95% confidence interval for the
experimental arm relative to control arm will be esti-
mated by proportional hazard regression [23-25] with
treatment, gender, age (< 30, ≥ 30 years), tumour size (<
70 ml, ≥ 70 ml), compression of OAR (yes/no) as cov-
ariates. A logistic regression analysis [26] will be carried
out to identify relevant prognostic factors. Benefit from
intervention (yes or no) will be defined as belonging to
the patients groups (low-risk, high-risk group) which lay
above the 50% percentile of LPFS.
The analyses of OS, PFS and metastasis free survival
will be conducted using log-rank test. The Kaplan-Meier
method will be used to obtain the estimates of the survi-
val functions and the 95% confidence intervals will be
estimated using Greenwood’s formula. Covariates will
not be included in the calculation.
All of these secondary analyses will be conducted at
the 0.05 level of significance.
Descriptive statistics will be provided for all other sec-
ondary endpoints. Additional exploratory analyses will be
used as appropriate. Generally, results will be given by
summaries of the data as indicated above together with the
test statistics and their associated p-values. Appropriate
confidence intervals of estimates of effect will be given to
quantify the degree of uncertainty of the point estimates.
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Safety Analysis
The safety analysis will be based on the safety popula-
tion. The assessment of safety will be based mainly on
the frequency of adverse events or serious adverse
events the acute and late toxicities and on the number
of laboratory values that fall outside of pre-determined
ranges and/or show prominent worsening. Furthermore,
the most common AEs (those occurring in at least 10%
of the treatment group) will be determined. Any other
information collected (e.g. severity or relatedness to
study drug) will be listed as appropriate. Incidence rates
and exact Pearson-Clopper 95% confidence bounds [27]
of AE will be summarized.
Interim Analysis
There is one planned interim analysis. The purpose for
performing the interim analysis is to support a possible
early detection of the superior therapy. In case of reach-
ing a critical value of 2.9626 in the interim analysis the
underlying therapy should neither be used for any
further patients treated within the study nor for any
patients outside of the study.
The interim analysis will be performed as soon as 50%
of the expected events have occurred. Assuming that rate
of recruitment proceeds at the rate estimated for this
study the time of the interim analysis will be approxi-
mately 7 years after the first patient is entered. This time
point is after the end of recruitment. For this reason the
interim analysis does not have the goal to stop the study
early and should not define a critical value of early stop-
ping for futility. Independent of the result of the interim
analysis the study should continue as planned with the
recruited and already treated patients.
Interim statistical hypothesis tests will be performed
only for the primary efficacy endpoint, LPFS. The log-
rank test identical to the primary analysis will be per-
formed at the scheduled interim analysis and compared
to group sequential boundary based on the current
information time. The LPFS curve estimated by the
method of Kaplan-Meier will be summarized for each
treatment group. The hazard ratio will also be esti-
mated. The interim safety report will review all aspects
of the data collected for each subject. Other important
additional factors that reflect the integrity of the proto-
col will be addressed in the interim report.
A group sequential design with an O’Brien and Flem-
ing alpha spending function is used to control the type I
error. The nominal one-sided significance level for the
interim analysis determined by using the O’Brien-Flem-
ing stopping rule is 0.0015.
Ethical and legal aspects
The study plan has been submitted to the ethics com-
mittee of the Medical faculty Heidelberg for approval.
The written approval by the ethics committee has been
already obtained. Additionally, we received the positive
vote of Bundesamt für Strahlenschutz for this study.
Prior to initiation of the treatment, patients will be
informed about the goals of the trial in a conversation.
Potential advantages and treatment related risks will be
discussed with the patient. A written consent will be
obtained and documented. The patient will be informed
about the possibility to withdraw his agreement to parti-
cipate in the study at any time without giving reasons.
The responsible physician will inform the patient in his
own language if possible and keep a record of this in
the patient chart. The informed consent form will be
signed. In case of cancellation the patient will be offered
standard therapy.
The coordinating investigator has to subscribe to an
insurance policy covering, in its terms and provisions,
its legal liability for injuries caused to participating per-
sons and arising out of this research performed strictly
in accordance with the scientific protocol as well as with
applicable law and professional standards.
Any impairment of health which might occur in con-
sequence of trial participation must be notified to the
insurance company. The subject is responsible for notifi-
cation. The insured person will agree with all appropri-
ate measures serving for clarification of the cause and
the extent of damage as well as the reduction of
damage.
During the conduct of the trial, the subject must not
undergo other clinical treatment except for cases of
emergency. The subject is bound to inform the investi-
gator immediately about any adverse events and addi-
tional drugs taken. The terms and conditions of the
insurance will be handed out to the subject on request.
The insurance company has to be informed about all
amendments that could affect subjects’ safety.
Discussion
This study is designed as a prospective monocentric
randomised phase III trial. The trial will be carried out
at HIT centre. Proton therapy is the gold standard in
the treatment of skull base chordomas. However, high-
LET beams such as carbon ions theoretically offer biolo-
gic advantages by enhanced biologic effectiveness in
slow-growing tumours. Up until now it was impossible
to compare two different particle therapies, i.e. proton
and carbon ion therapy directly with each other at the
same institution. The aim of this study is to find out,
whether the biological advantages of carbon ion therapy
mentioned above can also be clinically confirmed.
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